AHA 2020 | Omega-3 Fatty Acids Provide No Cardiovascular Benefits and Cause More Atrial Fibrillation

Results confirm the interim analysis, whereby the study was suspended for futility. Omega-3 fatty acids do not reduce cardiovascular events in patients with high triglycerides and low HDL.

Previous studies, such as REDUCE-IT, had shown positive results, but given this new research (presented at the American Heart Association [AHA] 2020 Congress and simultaneously published in JAMA), we need to come to terms with the fact that omega-3 fatty acids provide no benefit.

The problem in REDUCE-IT was that the control arm received mineral oil. That has a pro-inflammatory effect: it increases LDL, apolipoprotein B, and C reactive protein. All of that supported the interpretation that the differences between treatment arms were linked to the benefit derived from omega 3 acids, when they were probably due to the adverse events in the control group.

However, in the STRENGTH study, the control arm used corn oil, which has a neutral effect.

The study included 13,078 patients under statin treatment, presenting high risk for cardiovascular events, with high triglycerides (180 to 500 mg/dl), and low HDL (<42 mg/dl in males and <47 mg/dl in women).


Read also: AHA 2020 | RIVER: Rivaroxaban as Alternative to Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Mitral Valve.


Participants were randomized to corn oil or omega 3 fatty acids (such as eicosapentaenoic acid and docosahexaenoic acid).

At a mean 42 months of follow-up, omega 3 fatty acids did not reduce cardiovascular death, infarction, coronary revascularization, or hospitalization for unstable angina (12.0% vs. 12.2%; hazard ratio [HR]: 0.99; 95% confidence interval [CI]: 0.90-1.09).

There was an increased risk for new atrial fibrillation (2.2% vs. 1.3%; HR: 1.69; 95% CI: 1.29-2.21) with omega 3, which is consistent with the results of REDUCE-IT.

STRENGTH

Original Title: Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial.

Reference: Nicholls SJ et al. JAMA. 2020; Epub ahead of print y presentado en el congreso AHA 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TAVR and Anticoagulation: What Should We Do?

Transcatheter aortic valve replacement (TAVR) has consolidated as a valid strategy for certain groups of patients. However, approximately one third of those who require...

Direct Oral Anticoagulants for Ventricular Thrombus After STEMI

While the incidence of intracavitary thrombi after acute myocardial infarction (AMI) has decreased thanks to optimized primary angioplasty times, some studies report rates of...

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Bicuspid Valves: Higher Prosthesis Mismatch?

TAVR indication is steadily advancing onto younger, lower risk patients.  The presence of bicuspid aortic valves (BAV) has been observed in 0.5% to 2% of...

ROLLER COASTR-EPIC22: Comparison of Plaque Modification Techniques in Severely Calcified Coronary Lesions

The presence of coronary calcium significantly limits the success of percutaneous coronary interventions (PCI), primarily due to suboptimal stent expansion. This can lead to...

Edge-to-Edge Repair in Central and Non-Central Mitral Regurgitation

Mitral regurgitation (MR) is a common condition, with approximately 3.5% prevalence in individuals under 65, increasing to 7.7% in those over 75. It can...